IV Line Administration Strategy for Cefepime, Vancomycin, and Norepinephrine
Use the left wrist 22-gauge line for vancomycin and administer cefepime through the second port of the right forearm 20-gauge line (separate from the norepinephrine port).
Rationale and Administration Details
Primary Recommendation
The safest approach is to keep norepinephrine isolated on its dedicated port of the right forearm 20-gauge line and use the second available port on that same line for cefepime 1. Vancomycin should run through the left wrist 22-gauge line 2.
Key reasoning:
- Norepinephrine must never be interrupted or share a line with incompatible medications during critical vasopressor support
- Cefepime and vancomycin are physically and chemically compatible during Y-site administration 3, but the FDA label explicitly states that during cefepime infusion "it is desirable to discontinue the other solution" 1
- The 20-gauge right forearm line provides better flow rates and dilution for both the vasopressor and antibiotic
- Separating vancomycin to a different extremity eliminates any risk of inadvertent vasopressor interruption
Specific Administration Protocol
For Cefepime (2 mg/mL in 50 mL NS):
- Administer through the second port of the right forearm 20-gauge line (not the norepinephrine port)
- Infuse over 30 minutes minimum 1
- Total dose: 100 mg (50 mL × 2 mg/mL)
- Do NOT interrupt norepinephrine during cefepime administration
For Vancomycin (4 mg/mL in 250 mL NS):
- Administer through either port of the left wrist 22-gauge line
- Infuse over at least 60 minutes (for 1 gram dose) 2
- Total dose: 1000 mg (250 mL × 4 mg/mL)
- The 22-gauge line is adequate for this infusion rate
For Norepinephrine (1 µg/mL):
- Continue uninterrupted on its dedicated port of the right forearm 20-gauge line
- Never share this port or interrupt this infusion
Critical Safety Considerations
Vasopressor Protection
The norepinephrine infusion is your highest priority medication in a hemodynamically unstable patient. Any interruption risks precipitous blood pressure drops and end-organ hypoperfusion. The right forearm 20-gauge line with two ports allows you to maintain continuous vasopressor support while administering time-sensitive antibiotics through the second port.
Compatibility Nuances
While research demonstrates physical and chemical compatibility between cefepime and vancomycin during Y-site administration 3, the FDA label for cefepime recommends discontinuing other solutions during its infusion 1. This creates a practical dilemma that is resolved by using separate lines entirely—eliminating any compatibility concerns while maintaining all three infusions.
Line Selection Logic
- 20-gauge right forearm: Higher flow capacity, better for vasopressors and concurrent antibiotic administration, two available ports
- 22-gauge left wrist: Adequate for vancomycin infusion rates, keeps antibiotics on separate extremities for safety
Alternative Approach (If Absolutely Necessary)
If you must use the same line for cefepime and vancomycin (e.g., only one functional IV), they can be administered sequentially through the left wrist line:
- Start vancomycin first (60+ minute infusion)
- Flush line thoroughly with 10-20 mL normal saline 1
- Then administer cefepime (30 minute infusion)
- Keep norepinephrine completely isolated on the right forearm line
However, this delays antibiotic administration and is not the preferred approach when you have four available ports across two lines.
Common Pitfalls to Avoid
- Never use the norepinephrine port for anything else—even "compatible" medications can cause flow rate changes or inadvertent interruptions
- Do not attempt Y-site administration of cefepime with norepinephrine—no compatibility data exists and the risk is unacceptable
- Avoid the temptation to run both antibiotics simultaneously through Y-site on the left wrist line—while compatible 3, this creates unnecessary complexity and the FDA guidance suggests avoiding it 1
- Do not use IV push administration for cefepime in critically ill patients—recent data suggests worse outcomes compared to intermittent infusion 4